Literature DB >> 17686497

Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol.

Anders Borgkvist1, Daniel Marcellino, Kjell Fuxe, Paul Greengard, Gilberto Fisone.   

Abstract

CB1 receptor agonists increase the state of phosphorylation of the dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at the cAMP-dependent protein kinase site, Thr 34. This effect, which occurs in the medium spiny neurons of the striatum, has been proposed to mediate the motor depressant action of cannabinoids. In this study, we have examined the effect produced by systemic administration of Delta(9)-tetrahydrocannabinol (THC), the major component of marihuana and hashish, on DARPP-32. We show that THC increases DARPP-32 phosphorylation at Thr 34 both in dorsal striatum and nucleus accumbens. Time-course and dose-response experiments indicate that DARPP-32 phosphorylation is maximal 30 min following administration of 10mg/kg of THC. The THC-mediated increase in DARPP-32 phosphorylation is reduced by administration of the CB1 receptor antagonist, SR141716A (3mg/kg). A similar attenuation of the effect of THC is also exerted by suppression of cAMP signaling achieved using the dopamine D1 receptor antagonist, SCH23390 (0.125 mg/kg), or the adenosine A2A receptor antagonist, KW6002 (3mg/kg). These results indicate that, in the striatum, THC promotes PKA-dependent phosphorylation of DARPP-32 in striatal medium spiny neurons expressing dopamine D1 and adenosine A2A receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17686497     DOI: 10.1016/j.neuropharm.2007.06.025

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  13 in total

Review 1.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Protein kinases and addiction.

Authors:  Anna M Lee; Robert O Messing
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 4.  Theoretical considerations on the topological organization of receptor mosaics.

Authors:  Agnati Luigi Francesco; Fuxe Kjell; Woods Amina; Genedani Susanna; Guidolin Diego
Journal:  Curr Protein Pept Sci       Date:  2009-12       Impact factor: 3.272

5.  Adenosine A2a Receptor Blockade Diminishes Wnt/β-Catenin Signaling in a Murine Model of Bleomycin-Induced Dermal Fibrosis.

Authors:  Jin Zhang; Carmen Corciulo; Hailing Liu; Tuere Wilder; Mayumi Ito; Bruce Cronstein
Journal:  Am J Pathol       Date:  2017-06-28       Impact factor: 4.307

6.  Opposite function of dopamine D1 and N-methyl-D-aspartate receptors in striatal cannabinoid-mediated signaling.

Authors:  Tanya L Daigle; William C Wetsel; Marc G Caron
Journal:  Eur J Neurosci       Date:  2011-11       Impact factor: 3.386

7.  Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse Forebrain.

Authors:  Matthew F Lazenka; Aaron J Tomarchio; Aron H Lichtman; Paul Greengard; Marc Flajolet; Dana E Selley; Laura J Sim-Selley
Journal:  J Pharmacol Exp Ther       Date:  2015-06-22       Impact factor: 4.030

Review 8.  CB(1) cannabinoid receptors and their associated proteins.

Authors:  Allyn C Howlett; Lawrence C Blume; George D Dalton
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 9.  Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia.

Authors:  Kjell Fuxe; Daniel Marcellino; Amina S Woods; Leo Giuseppina; Tiziana Antonelli; Luca Ferraro; Sergio Tanganelli; Luigi F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2009-01-21       Impact factor: 3.575

10.  Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats.

Authors:  Virgili Pérez; Victoria Sosti; Antonia Rubio; Manel Barbanoj; Ignasi Gich; José Rodríguez-Alvarez; Jaime Kulisevsky
Journal:  J Neural Transm (Vienna)       Date:  2009-05-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.